RDZN

Roadzen is a legitimate global insurtech — commission and fee revenue from AXA, SCOR, Jaguar Land Rover and Mercedes partnerships, an FY2026 top line of $55.0M growing 24.2%, and a loss that narrowed sharply from -$72.9M to -$22.5M. On the income statement alone the trajectory is improving: operating loss halved-plus (+77% YoY) and net margin went from -165% (FY2024) toward -40.9%. If you only read the P&L, this looks like a turnaround.

The balance sheet says otherwise, and it dominates the call. Stockholders' equity is NEGATIVE -$29.6M against a -$246M accumulated deficit, so the standard leverage read (liabilities/equity of -2.67x) is meaningless except as a flag that the company is technically insolvent on a book basis. Cash is just $6.58M while operating cash flow burned -$20.3M this year — barely four months of runway. Worse, current liabilities of $58.3M swamp current assets of $32.3M (negative working capital of ~$26M), and $9.83M of debt is current (up 238%) with long-term debt exploding to $15.6M. This company must raise capital imminently or restructure; shares are already up 13.8% YoY from dilution, and more is the base case. R&D was gutted 89% to $408K — a survival cut that undercuts the AI-platform story management is selling in the MD&A.